<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="affordable antiretroviral supplies. Specifically, both sought to procure and provide" exact="efavirenz" post="(marketed as Sustiva by Merck) and lopinavir/ritonavir (marketed as"/>
 <result pre="efavirenz (marketed as Sustiva by Merck) and lopinavir/ritonavir (marketed as" exact="Kaletra" post="by AbbVie, then Abbott Laboratories) to their patients. In"/>
 <result pre="their patients. In initial price negotiations with Thailand, Merck offered" exact="efavirenz" post="at the price of US$500 per patient per year"/>
 <result pre="drugs from India at a significantly lowered cost â€&quot; generic" exact="efavirenz" post="at US$224 PPPY and generic lopinavir/ritonavir at US$676 PPPY"/>
 <result pre="PPPY [8]. Like Thailand, Brazil issued a compulsory license for" exact="efavirenz" post="in 2007. Merck initially offered efavirenz to Brazil at"/>
 <result pre="a compulsory license for efavirenz in 2007. Merck initially offered" exact="efavirenz" post="to Brazil at the price of US$760 PPPY. By"/>
 <result pre="compulsory license for efavirenz, Brazil was able to generically import" exact="efavirenz" post="at US$170 per patient/y. However, unlike Thailand, Brazil did"/>
</results>
